Guobang Pharma Ltd (605507) — Working Capital to Net Assets Ratio
Guobang Pharma Ltd (605507) has a Working Capital to Net Assets ratio of 45.4% as of March 2026. Working capital of CN¥3.96 Billion (current assets of CN¥6.53 Billion minus current liabilities of CN¥2.57 Billion) is measured against net assets of CN¥8.72 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See 605507 net asset quality score to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Guobang Pharma Ltd Working Capital to Net Assets (2017–2025)
This chart shows how Guobang Pharma Ltd's Working Capital to Net Assets ratio has evolved across 9 annual periods from 2017 to 2025. As of March 2026, the ratio stands at 45.4%, reflecting working capital of CN¥3.96 Billion against net assets of CN¥8.72 Billion CNY. Check 605507 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Guobang Pharma Ltd (2017–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Guobang Pharma Ltd from 2017 to 2025, covering 9 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see market value of Guobang Pharma Ltd.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 49.0% | CN¥4.19 Billion | CN¥8.56 Billion | CN¥6.11 Billion | CN¥1.92 Billion | ▲ +7.8 pp |
| 2024 | 41.2% | CN¥3.32 Billion | CN¥8.05 Billion | CN¥5.87 Billion | CN¥2.56 Billion | ▲ +0.9 pp |
| 2023 | 40.3% | CN¥2.99 Billion | CN¥7.44 Billion | CN¥5.44 Billion | CN¥2.45 Billion | ▼ -5.4 pp |
| 2022 | 45.7% | CN¥3.27 Billion | CN¥7.15 Billion | CN¥5.13 Billion | CN¥1.86 Billion | ▼ -8.1 pp |
| 2021 | 53.8% | CN¥3.41 Billion | CN¥6.35 Billion | CN¥4.57 Billion | CN¥1.15 Billion | ▲ +26.3 pp |
| 2020 | 27.4% | CN¥898.70 Million | CN¥3.27 Billion | CN¥2.87 Billion | CN¥1.97 Billion | ▼ -17.9 pp |
| 2019 | 45.4% | CN¥1.19 Billion | CN¥2.62 Billion | CN¥2.76 Billion | CN¥1.57 Billion | ▲ +2.3 pp |
| 2018 | 43.1% | CN¥1.12 Billion | CN¥2.59 Billion | CN¥2.83 Billion | CN¥1.72 Billion | ▲ +15.3 pp |
| 2017 | 27.8% | CN¥613.21 Million | CN¥2.21 Billion | CN¥2.43 Billion | CN¥1.81 Billion | — |